azelnidipine has been researched along with Diabetic Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Date, M; Ishii, K; Ito, H; Iwakura, K; Nagano, T; Nakamura, F; Takiuchi, S | 1 |
| Kain, V; Kumar, S; Sitasawad, SL | 1 |
1 trial(s) available for azelnidipine and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic Cardiomyopathies; Dihydropyridines; Echocardiography; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
1 other study(ies) available for azelnidipine and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dihydropyridines; Male; Myocardial Contraction; Myocardium; Oxidative Stress; Phosphoproteins; Rats; Rats, Wistar; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Superoxides; Time Factors; Troponin I; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |